These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8302472)

  • 21. [Purpura fulminans in the newborn. Report of two cases successfully treated with heparin and antithrombin III].
    Ficuccilli F; Iacobini M; Beglieri MR; Papoff P; Mancuso M; Caradonna A; Donato AI; Colarizi P
    Minerva Pediatr; 1997 Dec; 49(12):571-7. PubMed ID: 9577159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease.
    Peres E; Kintzel P; Dansey R; Baynes R; Abidi M; Klein J; Ibrahim RB; Abella E
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):203-7. PubMed ID: 18388499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombin deficiency in special clinical syndromes--Part I: panel discussion.
    Semin Hematol; 1995 Oct; 32(4 Suppl 2):37-41. PubMed ID: 8821208
    [No Abstract]   [Full Text] [Related]  

  • 24. Antithrombin for severe sepsis? Try it again, but without heparin!
    Jilma B
    Thromb Haemost; 2006 May; 95(5):755. PubMed ID: 16676061
    [No Abstract]   [Full Text] [Related]  

  • 25. [Discrepancy of biological antithrombins measured as progressive activity and heparin cofactor in a family with antithrombin III deficiency].
    Matsuo T; Ohoki Y; Matsuo O
    Rinsho Byori; 1982 Sep; 30(9):1033-6. PubMed ID: 7176137
    [No Abstract]   [Full Text] [Related]  

  • 26. The transient transfer of plasma antithrombin-III to an extraplasmatic body compartment during haemodialysis.
    Jespersen J
    Thromb Res; 1981 Jun 1-25; 22(5-6):693-6. PubMed ID: 7302912
    [No Abstract]   [Full Text] [Related]  

  • 27. [Three families with hereditary antithrombin III deficiency: the use of antithrombin III concentrate in one of the patients through the course of mastectomy (author's transl)].
    Hirasawa Y; Hayashi M; Nagaoka T; Kuto F; Tokuhiro H
    Nihon Ketsueki Gakkai Zasshi; 1981 May; 44(3):683-9. PubMed ID: 7331701
    [No Abstract]   [Full Text] [Related]  

  • 28. Replacement therapy in patients with hereditary antithrombin III deficiency.
    Menache D
    Semin Hematol; 1991 Jan; 28(1):31-8. PubMed ID: 2017690
    [No Abstract]   [Full Text] [Related]  

  • 29. Paradoxical behaviour of antithrombin III during hemodialysis and its prevention with prostacyclin.
    Turney JH; Fewell M; Williams LC; Dodd N; Weston MJ
    Clin Nephrol; 1982 Jan; 17(1):31-5. PubMed ID: 7035043
    [No Abstract]   [Full Text] [Related]  

  • 30. Anticoagulation therapy for renal insufficiency after burns.
    Ono I; Ohura T; Azami K; Hoshi M; Hasegawa T
    Burns Incl Therm Inj; 1984 Dec; 11(2):104-10. PubMed ID: 6525533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired antithrombin deficiency following severe traumatic injury: rationale for study of antithrombin supplementation.
    Owings JT; Gosselin R
    Semin Thromb Hemost; 1997; 23 Suppl 1():17-24. PubMed ID: 9156418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antithrombin III in the acute promyelocytic leukemias].
    Roncalés FJ; Juncá J; Tuset E
    Sangre (Barc); 1994 Apr; 39(2):148-9. PubMed ID: 8059294
    [No Abstract]   [Full Text] [Related]  

  • 33. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction.
    Hayakawa M; Sawamura A; Yanagida Y; Sugano M; Hoshino H; Gando S
    Shock; 2008 Dec; 30(6):649-52. PubMed ID: 18496242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombin III. Key factor in extracorporeal circulation.
    Ranucci M
    Minerva Anestesiol; 2002 May; 68(5):454-7. PubMed ID: 12029263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Benefits and risks of antithrombin III concentrates].
    Conard J
    Ann Fr Anesth Reanim; 1992; 11(3):330-1. PubMed ID: 1503313
    [No Abstract]   [Full Text] [Related]  

  • 37. Inherited antithrombin deficiency and end stage renal disease.
    Hara T; Naito K
    Med Sci Monit; 2005 Nov; 11(11):RA346-54. PubMed ID: 16258410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antithrombin III in intensive therapy].
    Baudo F; Caimi TM; Decataldo F; Calori G
    Minerva Anestesiol; 1999; 65(1-2 Suppl 1):71-6. PubMed ID: 10206028
    [No Abstract]   [Full Text] [Related]  

  • 39. [Congenital antithrombin III deficiency].
    Tsuji H; Nakagawa M
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):5-8. PubMed ID: 9851071
    [No Abstract]   [Full Text] [Related]  

  • 40. [Congenital antithrombin III deficiency. Use of concentrates in the prevention of thromboembolic episodes].
    Velasco F; Andrés P; Torres A
    Med Clin (Barc); 1985 Oct; 85(10):429. PubMed ID: 4079498
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.